...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Anticancer Research: International Journal of Cancer Research and Treatment >Evaluation of the prognostic value of CD44 in glioblastoma multiforme.
【24h】

Evaluation of the prognostic value of CD44 in glioblastoma multiforme.

机译：CD44在多形性胶质母细胞瘤中的预后价值评估。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND/AIM: Glioblastoma and astrocytoma are the most common brain tumors affecting adults 45-60 years of age. The poor prognosis for glioblastoma patients results from recurrence after treatment. There is therefore an urgent need to develop diagnostic and prognostic markers as well as new therapies. PATIENTS AND METHODS: Microarray analyses of clinical specimens from glioblastoma patients were used to identify potential tumor markers. Expression of candidate genes was analyzed by real-time reverse transcription-polymerase chain reaction and by immunoblotting and immunohistochemistry. RESULTS: Five potential markers (CD44 antigen (CD44), growth arrest and DNA-damage-inducible, alpha (GADD45A), fibronectin 1 (FN1), CD63 antigen (CD63) and secreted phosphoprotein 1 (SPP1)) showed expression patterns that correlated significantly with malignant glioma. In particular, expression of the CD44 antigen was elevated in more severe tumor types, and higher in tumor cores than in peripheral regions. However, lower levels of CD44 expression surprisingly correlated with lower survival. CONCLUSION: The CD44 antigen is a promising candidate for further development as a prognostic and therapeutic tool.
机译：背景/目的：胶质母细胞瘤和星形细胞瘤是影响45-60岁成年人的最常见脑肿瘤。胶质母细胞瘤患者预后差是由于治疗后复发。因此，迫切需要开发诊断和预后标志物以及新疗法。患者和方法：对胶质母细胞瘤患者的临床标本进行微阵列分析，以鉴定潜在的肿瘤标志物。通过实时逆转录-聚合酶链反应以及免疫印迹和免疫组织化学分析候选基因的表达。结果：五个潜在的标志物（CD44抗原（CD44），生长停滞和DNA损伤诱导型，α（GADD45A），纤连蛋白1（FN1），CD63抗原（CD63）和分泌的磷蛋白1（SPP1））显示了相关的表达模式恶性神经胶质瘤明显。特别地，CD44抗原的表达在更严重的肿瘤类型中升高，并且在肿瘤核心中比周围区域更高。但是，较低水平的CD44表达令人惊讶地与较低的存活率相关。结论：CD44抗原是有希望的候选物，可作为预后和治疗工具进一步发展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号